Sunday, June 1, 2025
20.6
C
Bengaluru
My account
Get into your account.
Hot topics
Talent Management
A diverse, summer issue with articles on topics ranging from content marketing to the role of experience in a VUCA world. Also, the latest book for Medical Reps reviewed by Prof. Vivek Hattangadi
Digital in Pharma and RoI – What and How to Measure Metrics that Matter
To be able to measure the RoI on digital in pharma, it is necessary to understand customers as individuals and create newer segmentation based on these needs and interests. This calls for the NextGen RCPA of data collection and personalized communications that engage customers, based on which pharma must create customer experiences that matter to them.
If your content does not scratch, where it itches the customers, digital or phygital, customers will not feel at home (comfortable, delighted, and wants more), which is what matters. Not a digital euphoria, which will soon die down as customers simply ignore it as they did when pharma launched a plethora of webinars.
Interview with Ajit Singh, Chairman, ACG
Special interview with the Chairman of ACG and an invitation to "Pharmaceutical Marketing in the New Age" - a conference presented by ACG in partnership with MedicinMan
IMS Health Market Reflection Report for September 2016
The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.
Crafting a Digital Strategy: The Roadmap for 2021
In many situations, technology upgradation is often construed as digital transformation. In a recently conducted survey by Altimeter, 88% of companies said that they were undergoing ‘digital transformation’ but only 25% said that they did so with the purpose beyond investing in new technology. The real definition of digital transformation is the realignment of, or new investment in technology, business models, and processes to create value for customers in a dynamic digital economy.
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Hot topics
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
How Did Telma Become a 1000+ Cr Brand?
The untold story of Glenmark's phenomenal success in building...
Indian Pharma Market Highlights
Indian Pharma Market highlights for the month of October 2018, brought to you by AIOCD Pharma Softech Awacs.
Medical Reps will Remain – What will be their Future Role?
There was a phase when the industry feared that digital would eventually replace the medical sales representative but it appears that digital engagements work best when facilitated by an affable and knowledgeable person, who can personalize the information, and the conversation, to the doctor. In pharma, there’s no substituting face-to-face dialogue it seems. And why should it?
“Rather than digital replacing a person in pharma, the need of the hour is digitalizing the approach of person. The person and the technology are HERE TO STAY”, says Archis Joshi, Commercial Head at Dr. Reddy’s.
The sales role is getting tougher. Medical information, at one point pharma’s greatest value, is today much more freely available than it used to be. In the Indian market which is dominated by generic medicines lacking differentiation, simply informing doctors about the product, isn’t a viable prospect any more when it comes to piquing their interest.
“Why are brands that have been around for some time still unable to cross the marketing funnel and are still stuck at either the ‘awareness’ or the ‘interest’ stages, and unable to move towards the ‘purchase’ or ‘recommendation’ stages?” wonders Mehul Shukla, Director, Marketing Excellence at Cipla.
Is Pharma’s Business Model like McDonald’s? ...
Is Pharma’s business model like McDonald’s? Doing things over & over again without innovation?
McDonald’s is famous for its Hamburger University, a training facility at the McDonald’s Corporation global headquarters in Chicago, Illinois. It instructs high-potential restaurant managers in restaurant management.
More than 5,000 students attend Hamburger University each year and over 275,000 people have graduated with a degree in Hamburgerology.
Sound familiar? Pharma’s training has been on similar lines – hire people continuously and put them through the grind of mugging up essentials of drugs for diseases that the particular company sells.
While the McDonald’s model is ideal for its business of replication, it has outlived its utility in healthcare and drug companies are in danger of being reduced to mere suppliers of drugs to new digital platform businesses unless they learn to innovate.
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Newsletter
Get important news delivered directly to your inbox and stay connected!